Background: This study aimed to evaluate whether fear of hypoglycaemia (FOH) ispresent in diabetic patients receiving oral hypoglycemic agents or insulin and factorsthat can influence it. Methods: This study is a cross sectional survey of diabetic patients attendingendocrine clinics in Jordan University Hospital, King Abdullah University Hospital and Royal Medical Services, from June 2013 till may 2014. Results: Out of 326 approached 268 patients participated. The mean age ofparticipants was (49.81±14.09), and 141 (52.6%) were females. FOH was present in allpatients and with all antidiabetic medications. Among antidiabetic agents, patientstaking insulin were found to have the highest score of overall FOH (p<0.001). Level offear correlated with type of diabetes (p<0.01), and being female (p<0.01). Patientsworking in medical field behavioral fear scores were higher compared with patientsworking in non-medically related field (p<0.01). In addition, as the duration of diabetesincreases the overall FOH increases (p<0.01). It had been found that as the FOHincreases the quality of life decreases (p<0.001). Conclusion: Type of diabetes, age and type of antidiabetic agent affect FOH. Diabetes Mellitus duration and gender affect the behavioral scale of hypoglycaemia fear survey. FOH has been found to affect quality of life.
INTRODUCTION
Diabetes mellitus (DM) is a chronic condition caused by an absolute lack of insulin or relative lack of insulin as a result of impaired insulin secretion and action. Its hallmark is symptomatic glucose intolerance resulting in hyperglycemia and alterations in lipid and protein metabolism. In the long term, these metabolic abnormalities contribute to the development of macro and micro-complications such as cardiovascular disease (CVD), retinopathy, nephropathy, and neuropathy (1) .
According to the International Diabetes Federation (IDF) 382 million people have diabetes in 2013 and by 2035 this will rise to 592 million worldwide. The number of people with type2 diabetes is increasing in every country, 80% of people with diabetes live in low-and middleincome countries and the greatest number of people with diabetes are between 40 and 59 years of age (IDF, 2013) . In Jordan, the prevalence of diabetes in adult's ≥25 years of age is 17.1%, while an additional 7.8% of Jordanians have impaired glucose tolerance with no significant differences between women and men (2) .
The overall goal of diabetes management is to achieve and maintain controlled blood glucose and reduce the risk -78 -of long-term complications. Recent Studies have shown that intensive glycemic control can limits, delays or even prevents the chronic complications of diabetes. However; this way of management associated with an increased risk of hypoglycaemia (3) . Hypoglycaemia is common in diabetic patient; studies have shown that hypoglycaemic events occur in 24% to 60% of diabetic patients (4) .
Hypoglycaemia is defined as abnormally low plasma glucose concentration which may expose the patients to potential harm (5) .There are no defined or single threshold value for the symptoms of hypoglycaemia, however; patients must be alerted to the risk of hypoglycaemia when plasma glucose is ≤ 70 mg/dl or ≤3.9mmol/L (5) .
The symptoms of hypoglycaemia are classified as neuroglycopenic or neurogenic (autonomic) which are further classified as adrenergic or cholinergic. Neuroglycopenic symptoms are caused by the direct low glucose level in the brain, and neurogenic symptoms are caused by perception of physiologic changes triggered by hypoglycaemia (6) (7) (8) .
Hypoglycaemia is considered as a true medical emergency which requires immediate recognition and treatment to prevent organ and brain damage. The symptoms of hypoglycaemia depend on the duration and the severity of hypoglycaemia and vary from autonomic activation, behavioural changes, altered cognitive function, to seizures or coma (3) . It can occur suddenly and it's characterized by unpleasant physical and psychological symptoms such as shaking, sweating, drowsiness, nausea, poor motor coordination, mental confusion, negative mood, and unconsciousness (9) (3) .
Repeated hypoglycaemic episodes lead to compromise physiologic and behavioural defences against future falling glucose concentration, causing a cycle of recurrent hypoglycaemia (10) . Untreated hypoglycaemia can cause a significant economic and personal burden, so the identification and prevention of hypoglycaemia can reduce diabetes burden by prevention of hypoglycaemia complications (11) .
The frequency of hypoglycaemic events in diabetic patients treated with oral antidiabetic (OAD) or incretinbased therapies are lower than patients treated with insulin, however; the incidence increases when incretin based therapies, especially glucagon like peptide-1 receptor agonists, are combined with sulphonylureas (12, 13) .
Given the potential life threatening nature of severe hypoglycaemia, it would not be surprising that many of diabetic patients have a significant fear of developing hypoglycaemia. This fear may have significant clinical implications for diabetes management. Patients with FOH may engage in 'over-compensatory behaviours' to avoid the aversive symptoms of past hypoglycaemic episodes, this may include taking less medication or overeating to avoid hypoglycaemia. The latter may result in poor metabolic control and increase the risk of serious health consequences associated with diabetes (14) .
The aim of this research was to evaluate level of FOH in diabetic patients receiving oral hypoglycaemic agents or insulin, and to investigate the factors that can influence FOH including.
Methodology
This study is cross sectional based survey targeting diabetic patients attending endocrine clinics at Jordan University Hospital (JUH), King Abdullah University Hospital (KAUH) and Royal Medical Services (RMS). Ethical approval was obtained from all participating institutions. Participants' verbal consent was obtained before any information was collected from them. Inclusion criteria: patients aged 18 years or older with DM who sought care at the outpatient clinics who have been diagnosed with DM for at least one year. The sample size of this study was calculated based on the average number of patients daily visiting endocrinology clinic in JUH, KAUH and RMS are 1000/month, sample size at a 95% confidence interval will be 370.
A structured interview based questionnaire was used. It included: 1) Patient information (demographics, diabetes assessment, other chronic conditions and current medication) 2) Hypoglycaemia fear survey: (HFS (15) . It consists of two subscales with a total of 27 items measuring behavioral and affective aspects of FOH. The behavior subscale (avoidance subscale) consisted of 10 items that measure an individual's behavior in his or her effort to avoid hypoglycaemia or the effects of hypoglycaemia. The second subscale (Worry), measuring the emotional/affective aspect of FOH, which consists of 17 items describing a person's concerns of hypoglycaemia and its consequences. The items are rated on a five-point Likert scale ranging from Never (1) to Always (5). Total FOH score was calculated by adding both subscale scores. The instrument has been translated to Arabic language and validated (face and content validation) by the authors and a physician. Data was analyzed using the Statistical Package for Social Sciences (SPSS) software version 20 including descriptive statistics, independent-Sample T-test, one way ANOVA, and Pearson correlation. Because of multiple comparisons, bonferroni correction was applied and all p values < 0.01 was considered statistically significant.
Results
Out of 326 patients invited to be enrolled in the study only 268 were actually included. Fifty four were excluded due to incomplete information or refusal to participatedue to lack of time or interest( Figure 1 ).
Figure 1: Patients recruitment flow chart
The average age of participants was 49.8, and 52.6% were females. Only 7.8% of the patients' population were working in a medically related field (Table1). The most commonly used diabetic management drug was metformin. The most commonly reported drug for co morbidities was a statin. Details are shown in Table 2 . In general, patients' level of worry was low, except for the fact that they were worried that hypoglycaemia would cause decrease or loss of consciousness. They were also worried that the loss of consciousness would lead to other health problems. The most frequently reported fear component was carrying pieces of sugar, the administration of food, in addition to reducing drug dose due to fear of hypoglycaemia. Patients' FOH; behaviour and worry results were detailed in Table 3 . Table 4 shows quality of life assessment in which; generally patients are satisfied with their situation, particularly they are mostly satisfied with their knowledge about their diabetes and current treatment, while they are not surely satisfied about time spent on exercise. Also, the least to worry about is "missing work "compared to "sometimes feel physically ill and passing away".
Field of employment was found to affect the behaviour part of FOH; patients working in the medical field behavioural score were higher than patients who are not. As the duration of diabetes increases the FOH behavioural and overall scores increase. Patients with higher HbA1c and fasting blood glucose level also scored higher in regard to FOH. As FOH increases the quality of life decreases, younger patients had higher FOH score than elderly. Details are shown in Table 5 . As expected, patients with type 1 DM and those taking insulin had the highest FOH scores. Those taking DPP-4 inhibitor had the lowest score, details showed in Table 6 . 
Discussion
This study found that as the FOH increases, the quality of life decreases, this correlate with results of Lundkvist study in 2005 (16) . In general; FOH has a negative impact on quality of life, diabetes management and metabolic control, subsequent health outcomes and increased fear and anxiety (14, 15) . Like other diabetic patients globally, Jordanian patients have fear of hypoglycaemia with all of their antidiabetic drugs. As the diabetes self-management decreases, hypoglycaemia and the development of long-term complications associated with low glycemic control increases. Recurrent hypoglycaemic events are associated with increased health care costs and resources required to treat hypoglycaemic events, as well as personal financial costs and loss of productivity at school or work. Also fear and worry about future hypoglycaemia events interfere with patient's quality of life (17) . Health related quality-of-life (HRQoL) is affected by FOH in diabetic patients. It has been shown that patient with hypoglycaemia symptoms report more fear and worry of hypoglycaemia and more influenced by their diabetes compared with patients without hypoglycaemia symptoms (16) .
The most common causes for hypoglycaemia in diabetic patients are insufficient food (43% in type 1 diabetes mellitus (T1DM) and 47% in type 2 diabetes mellitus (T2DM; (18) . In this study patients reported that the often administered food, and reduction of antidiabetic medication dose when they feel the first sign of low blood sugar. The practice of patients is understandable, since the aggressiveness of therapy to achieve glycemic control is considered as most important risk factor for hypoglycaemia (19) . Other risk factors such that can cause hypoglycaemia include: antecedent hypoglycaemia, (13) alcohol, increased glucose utilization (e.g., exercise), female sex, sleep and decreased glucose and production -84 -(e.g., liver disease) (20) . Duration of diabetes, age and progressive insulin deficiency are also found to be associated with high risk of hypoglycaemia in patients with T2DM, which appear to be increased in patients who have received insulin for more than 10 years (11) . In this study females reported higher FOH scores than men. The duration of diabetes was also correlated with higher FOH score that is considered as important risk factor for severe hypoglycaemia. In this study; older patients FOH scores were lower than younger patients. This might be due to lack of awareness as over the time, symptoms of hypoglycaemia become less intense or even diminish altogether, resulting in hypoglycaemia unawareness in a significant proportion of diabetic patients, (21) . The latter is dangerous, as studies shows that hypoglycaemia unawareness leads to increased risk of sever hypoglycaemia by 6-fold in T1DM and 9-fold in T2DM (22, 23) .
Patients use insulin for diabetes management had the highest FOH score. It is reported that approximately 90% of diabetic patient who receive insulin have experienced hypoglycaemic events (10) . In T1DM individuals, they experience two events of symptomatic hypoglycaemia per week and one event of severe hypoglycaemia per year (10) . The incidence of hypoglycaemia events in T2DM
is one third of T1DM (10, 24) . Studies showed that the incidence of sever hypoglycaemic event per patient-year in insulin treated T2DM was 0.35 compared to an incidence of 1.15 per patient-year in T1DM (24) . Most of the hypoglycaemic events seen in T2DM because of the prevalence of disease is 20 times greater than that of T1DM and most of these patients will need insulin therapy (10) . The prevalence of an event varies according to the type of therapy. It ranges from 61.5% with the combination of sulfonylurea, metformin, insulin, to 30.5% with insulin alone; and 6% with metformin alone (25) . A hypoglycaemia event also reduces productivity and increases healthcare costs. The cost of hypoglycaemia event varies depend on the severity of the episode, and ranges from minimal (€63) for a mild episode, to very high (€3917) for a severe episode requiring hospitalization (26) .
In diabetic individuals, FOH increases the psychological distress associated with diabetes. This has a behavioural impact on diabetes management and metabolic control. Which is represented by taking a counteractive action to prevent hypoglycaemia by keeping high blood glucose or over treats the early signs of hypoglycaemia (15) . Some diabetic patients see hypoglycaemia events are more tangible than the possibility of future health problems. FOH has also been connected to state and trait anxiety. Studies have shown that in patients with both type 1 and type 2 diabetes there was a correlation between higher scores on the worry scale of the hypoglycaemia fear survey (HFS) and higher levels of trait anxiety and general fearfulness (27) . This may lead to a diminished ability to differentiate between anxiety and hypoglycaemia that could delay or prevent the patient from responding appropriately to hypoglycaemia, and thus, a more severe hypoglycaemic episode may occur (26) .
The unpleasant symptoms associated with hypoglycaemic event and its negative consequences may lead to anxiety or FOH in patients with diabetes. This may increase risk for keeping blood glucose levels high to avoid episodes by the diabetic patient when fear is high, thereby contributing to poorer metabolic control and subsequent health outcomes, FOH is considered as a major barrier for optimal blood glucose control and this may outweigh concerns about long-term consequences of the effects of hyperglycaemia (14) . In agreement with previous studies, this study showed high FOH score in patients on sulfonylurea or insulin because of the high incidence of hypoglycaemia with these agents (28, 29) .
These result are also related to the finding in study by (15) that FOH have a behavioural impact on diabetes management and metabolic control. This impact is represented by taking a counteractive action to prevent hypoglycaemia by keeping high blood glucose or over treating the early signs of hypoglycaemia.
Conclusions
FOH exists among patients taking hypoglycemic agents. FOH has been found to affect quality of life negatively. So further research is needed to specify this FOH more among agents used to treat diabetes in order to increase awareness and educate patients not to feel fear with agents without hypoglycaemia risk, taking into consideration not only antidiabetic agent, but also type of diabetes, age, diabetes duration and gender.
